NEU 6.41% $15.27 neuren pharmaceuticals limited

Phelan-McDermid Syndrome, page-85

  1. 1,139 Posts.
    lightbulb Created with Sketch. 537
    Interesting idea Mr T. Admittedly I’d be concerned that a buyback may not have the desired effect of increasing the share price which can happen with some companies. If Neuren is thinking about selling early, I would deem it a risk to spend money on share buybacks and would prefer dividends even at the risk of incurring significant tax burdens. I’d be devastated if the company spent a few hundred million dollars on share backs for a negligible gain when I could’ve held some of that money in my hot little hands lol
    Last edited by Eagle0: 17/07/23
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.